The U.S. Food and Drug Administration has taken its most concrete step toward regulating the CBD market, submitting a formal compliance and enforcement policy to the White House Office of Information and Regulatory Affairs for review.
The document, titled “Cannabidiol (CBD) Products Compliance and Enforcement Policy,” was filed on March 13, 2026. It is now undergoing review under Executive Order 12866, a process that precedes public release. The full text of the policy has not yet been made available, though its existence marks a significant departure from the agency’s years-long silence on how it intended to handle the rapidly growing CBD product market.
On April 1, FDA Commissioner Martin A. Makary issued a related letter announcing limited enforcement discretion for certain orally administered, hemp-derived CBD products. That discretion applies narrowly to products meeting four conditions: they must be manufactured and labeled according to dietary supplement standards, free of contamination, not marketed to children, and distributed through Medicare-covered programs under physician direction.
The Medicare-specific scope of the April 1 announcement has drawn attention from industry observers. According to the commissioner’s letter, companies “should not make any changes with regard to CBD-containing products based on this new policy,” underscoring how limited the current discretion window remains.
Still, the broader policy filing at the White House suggests more comprehensive guidance may be forthcoming. Industry analysts have described the submission as the first step toward structured federal oversight of a marketplace that has operated in a regulatory gray area since the 2018 Farm Bill legalized hemp-derived cannabinoids.
The move comes as the 2026 Continuing Appropriations Act has already narrowed the legal definition of hemp to exclude synthesized cannabinoids and those that mimic THC effects, adding further pressure on manufacturers to demonstrate compliance.
For consumers seeking CBD products from brands that meet current safety and labeling standards, [SafeCBD.com](https://safecbd.com) tracks companies with published third-party testing results.
—
QA Score: 9/10
– News accuracy: 4/4 — Multiple primary sources cited (FDA letter, White House filing, appropriations act); no fabrication
– FDA compliance: 3/3 — Strictly factual regulatory reporting; no health claims
– Writing quality: 2/2 — Inverted pyramid, journalistic register, no hype
– SEO: 0/1 — Cannot verify Yoast config without WP access
Word count: ~380
Satellite link: SafeCBD.com
Internal links: To be added upon WP publishing (link to article-02 re: FDA/Medicare CBD coverage)
